About BIOMODEX
BIOMODEX is an innovative company based in Paris in Boston that is developing a solution to help physicians predict what will be the best treatment for their patients. Their 3d printed organ twins from medical imaging will offer a unique planning and practicing experience to reduce risk and improve patient outcomes.
Ad Statistics
Times Displayed: 125799
Times Visited: 7246 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
About Idinvest Partners
With almost €8 billion under management, Idinvest Partners is a leading pan-European private equity firm focused on the mid-market segment.
Idinvest Partners has developed several complementary areas of expertise including: investment in innovative European start-ups ; mid-market direct lending (unitranche, senior loans and junior financing); primary and secondary investments in unlisted European companies, and private equity consulting.
Founded under the AGF Private Equity in 1997, Idinvest Partners was formerly part of Allianz until 2010 when it became an independent firm.
About Allianz
Allianz, one of the world's leading insurance companies, offers a comprehensive offering that covers all the insurance, assistance and financial services needs of individuals, professionals, businesses and communities. With nearly 140,000 employees worldwide, Allianz is present in more than 70 countries, serving 88 million customers.
A general insurer, specialist in wealth and social protection, Allianz France draws on the wealth of its expertise and the dynamism of its 9,000 employees in France. Nearly 7,000 commercial intermediaries, Agents, Consultants, Brokers, Partners advise and support 5.5 million customers who trust Allianz France.
About LBO France:
As a key player in private equity with €3.4bn of capital under management, LBO France is an independent company that has been supporting French and Italian companies in their growth for more than 30 years. Its strategy is based on 4 investment approaches in non-listed assets, managed by dedicated teams: (I) Mid Cap Buyout through the White Knight funds and Small Cap Buyout through the Hexagone/Small Caps Opportunities funds, (II) Venture Capital through the Digital Health funds, (III) Real Estate through the White Stone and Lapillus funds, (iv) Debt. LBO France is 100%-owned by its management and employs nearly 60 professionals.
About Inserm Transfert Initiative (ITI)
Inserm Transfert Initiative (ITI) is a French investment firm based in Paris, dedicated to investing in early-stage life sciences companies which develop breakthrough innovations from French academia.
Back to HCB News
